Moderna to Pay Immatics Up to $1.8 Billion in Cancer-Drug Deal
Moderna Inc. agreed to pay German biotechnology company Immatics NV as much as $1.8 billion in a broad-ranging, multiyear collaboration on developing cancer therapies using messenger RNA and other technologies. #press
